Semaglutide + B12 (Compounded Semaglutide)

Semaglutide + B12 (often with glycine) is one of the most commonly prescribed compounded peptide formulations for weight management. The rationale addresses a practical clinical concern: GLP-1 agonists like semaglutide slow gastric emptying and reduce food intake, which can lead to reduced nutrient absorption — particularly B12, which requires adequate gastric acid and intrinsic factor for absorption. Vitamin B12 deficiency is already common in the general population (estimated 6-20% of adults), and the reduced food intake and altered GI transit from semaglutide may compound this risk. Symptoms of B12 deficiency — fatigue, brain fog, weakness, and neuropathy — overlap with common semaglutide side effects, making deficiency easy to miss. Co-administering B12 is a simple prophylactic measure. Glycine is often added to compounded formulations as well. A 2025 study demonstrated that glycine supplementation in individuals with severe obesity improved metabolic markers including plasma triglycerides and aminotransferases, with evidence of enhanced detoxification pathways.

Semaglutide activates the GLP-1 receptor, enhancing glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite through central nervous system signaling. The 15-20% body weight reduction seen in clinical trials creates a significant caloric deficit. Vitamin B12 (cyanocobalamin or methylcobalamin) serves as a cofactor for methionine synthase and methylmalonyl-CoA mutase — enzymes critical for DNA synthesis, red blood cell formation, neurological function, and energy metabolism. During the substantial caloric restriction induced by semaglutide, ensuring adequate B12 status supports energy levels, cognitive function, and prevents the neurological complications of deficiency. This is not pharmacological synergy in the traditional sense — B12 does not enhance semaglutide's weight loss mechanism. Rather, it's a supportive combination that addresses a predictable nutritional gap created by the primary therapy.

Semaglutide has among the strongest evidence bases of any peptide — extensive Phase III programs (SUSTAIN, PIONEER, STEP trials) with thousands of patients, multiple FDA approvals, and published outcomes data in NEJM and other top journals. The weight loss efficacy (15-17% at the 2.4mg weekly dose) and cardiovascular benefit (20% MACE reduction in SELECT) are well-established. The B12 supplementation rationale is supported by observational data showing increased B12 deficiency risk with proton pump inhibitors and metformin — drugs that similarly affect GI absorption. While no RCT has specifically studied B12 co-administration with semaglutide, the clinical reasoning is straightforward and the risk of supplementation is essentially zero. The glycine addition is supported by a 2025 study showing metabolic benefits in obese individuals, though this studied glycine alone rather than in combination with GLP-1 therapy.

Semaglutide is administered as a weekly subcutaneous injection with a standard dose escalation schedule (0.25mg → 0.5mg → 1.0mg → up to 2.4mg for weight management). B12 is co-administered either in the same compounded injection or as a separate supplement (oral or injectable). Compounded formulations often include glycine as well. The dose escalation over 4-5 months is important for minimizing GI side effects. All protocols should be managed by a qualified clinician with regular monitoring.